Elizabeth J. Cathcart-Rake, M.D.

The purpsoe of this stduy is to compare anxiety scores before and after a nurse-led acupressure intervention; we hypothesize that true acupressure will significantly decrease anxiety scores, as compared with sham acupressure. Then, we will teach patients to self-administer true vs sham acupressure to test the efficacy of self-administered acupressure for anxiety. We will also investigate whether true vs sham acupressure alleviates nausea. The ultimate goal of this research is to mitigate acute anxiety experienced by patients with cancer, using well-tolerated and widely generalizable interventions.

The purpose of this study is to learn about potential side effects facing people who are undergoing treatments for their cancer, specifically, hair loss. While this is not a well-documented side effect of hormone-blocking medications (such as tamoxifen, letrozole, anastrozole, or exemestane), we have preliminary evidence that it is a problem for some patients getting this treatment.  This study will include some patients receiving the hormone therapy and some patients who are not, so we can better understand whether patients getting the hormonal therapy have more hair loss than patients who are not getting such.

The purpose of this study is to conduct interviews of Transgender and Gender Diverse (TGD) individuals to learn their perceptions of healthcare screenings.  

The purpose of this study is to document the beliefs, attitudes, and experiences regarding NIH cancer research participation expressed by SGM cancer patients. 

The purpose of this study is to test the safety, side effects, and best dose of monosialotetrahexosylganglioside (GM1) and whether it works in reducing or preventing chemotherapy-induced peripheral neuropathy (CIPN) in patients with breast cancer that has spread from where it first started (primary site) to other places in the body (metastatic) who are receiving treatment with paclitaxel.  

The purpose of this study is to probe into reasons why patients and healthcare providers might not discuss sexual orientation and gender identity as well as general sexual health issues in oncology clinics.